China SXT Pharmaceuticals (SXTC) Competitors $1.66 +0.10 (+6.41%) Closing price 04:00 PM EasternExtended Trading$1.62 -0.04 (-2.71%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SXTC vs. MTVA, NLSP, MYNZ, GTBP, HCWB, JAGX, ATNF, APLM, FRTX, and ENSCShould you be buying China SXT Pharmaceuticals stock or one of its competitors? The main competitors of China SXT Pharmaceuticals include MetaVia (MTVA), NLS Pharmaceutics (NLSP), Mainz Biomed (MYNZ), GT Biopharma (GTBP), HCW Biologics (HCWB), Jaguar Health (JAGX), 180 Life Sciences (ATNF), Apollomics (APLM), Fresh Tracks Therapeutics (FRTX), and Ensysce Biosciences (ENSC). These companies are all part of the "pharmaceutical products" industry. China SXT Pharmaceuticals vs. MetaVia NLS Pharmaceutics Mainz Biomed GT Biopharma HCW Biologics Jaguar Health 180 Life Sciences Apollomics Fresh Tracks Therapeutics Ensysce Biosciences China SXT Pharmaceuticals (NASDAQ:SXTC) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk. Do insiders and institutionals believe in SXTC or MTVA? 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 1.1% of MetaVia shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has higher valuation and earnings, SXTC or MTVA? China SXT Pharmaceuticals has higher revenue and earnings than MetaVia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.82M0.66-$3.10MN/AN/AMetaViaN/AN/A-$12.47MN/AN/A Does the media prefer SXTC or MTVA? In the previous week, MetaVia had 4 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 4 mentions for MetaVia and 0 mentions for China SXT Pharmaceuticals. MetaVia's average media sentiment score of 0.28 beat China SXT Pharmaceuticals' score of 0.00 indicating that MetaVia is being referred to more favorably in the news media. Company Overall Sentiment China SXT Pharmaceuticals Neutral MetaVia Neutral Which has more volatility & risk, SXTC or MTVA? China SXT Pharmaceuticals has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, MetaVia has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Do analysts prefer SXTC or MTVA? MetaVia has a consensus price target of $7.50, indicating a potential upside of 756.65%. Given MetaVia's stronger consensus rating and higher probable upside, analysts clearly believe MetaVia is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MetaVia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in SXTC or MTVA? China SXT Pharmaceuticals received 78 more outperform votes than MetaVia when rated by MarketBeat users. However, 100.00% of users gave MetaVia an outperform vote while only 61.65% of users gave China SXT Pharmaceuticals an outperform vote. CompanyUnderperformOutperformChina SXT PharmaceuticalsOutperform Votes8261.65% Underperform Votes5138.35% MetaViaOutperform Votes4100.00% Underperform VotesNo Votes Is SXTC or MTVA more profitable? China SXT Pharmaceuticals' return on equity of 0.00% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A MetaVia N/A -189.12%-122.31% SummaryChina SXT Pharmaceuticals beats MetaVia on 8 of the 14 factors compared between the two stocks. Get China SXT Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTC vs. The Competition Export to ExcelMetricChina SXT PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / Sales0.66250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book0.056.466.794.50Net Income-$3.10M$143.98M$3.23B$248.18M7 Day Performance-0.60%3.04%4.07%1.14%1 Month Performance62.75%7.44%12.52%15.18%1 Year Performance-81.80%-2.46%16.83%6.55% China SXT Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTCChina SXT Pharmaceuticals0.2506 of 5 stars$1.66+6.4%N/A-83.9%$1.20M$1.82M0.0090MTVAMetaVia1.8741 of 5 stars$0.70-3.9%$12.00+1,612.6%N/A$6.07MN/A0.008News CoverageEarnings ReportAnalyst ForecastNLSPNLS PharmaceuticsN/A$1.64flatN/A+877.4%$5.90MN/A0.006News CoveragePositive NewsGap UpMYNZMainz Biomed2.285 of 5 stars$2.54+3.7%$14.00+451.2%-90.7%$5.89M$893,991.00-0.0430Gap DownGTBPGT Biopharma2.9727 of 5 stars$2.32+2.2%$11.00+374.1%-72.3%$5.88MN/A-0.338Earnings ReportGap DownHCWBHCW Biologics1.5632 of 5 stars$5.21-15.7%N/A-79.3%$5.85M$2.57M-5.2140Earnings ReportJAGXJaguar Health1.601 of 5 stars$7.77-8.7%N/A-97.7%$5.74M$11.69M0.0050News CoverageEarnings ReportAnalyst ForecastHigh Trading VolumeATNF180 Life SciencesN/A$1.10+0.9%N/A-24.8%$5.71MN/A0.007Earnings ReportGap UpAPLMApollomicsN/A$5.14-9.5%N/A-83.2%$5.67M$1.22M0.0045Positive NewsGap DownFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+2.0%$5.59M$10.06M-0.6620ENSCEnsysce Biosciences0.2301 of 5 stars$2.19+0.9%N/A-78.2%$5.19M$2.23M-0.0810Gap Up Related Companies and Tools Related Companies MetaVia Alternatives NLS Pharmaceutics Alternatives Mainz Biomed Alternatives GT Biopharma Alternatives HCW Biologics Alternatives Jaguar Health Alternatives 180 Life Sciences Alternatives Apollomics Alternatives Fresh Tracks Therapeutics Alternatives Ensysce Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SXTC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China SXT Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China SXT Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SXTC Stock Free SXTC Stock Alerts